Aphria (OTCQB:APHQF) enters into joint supply agreement with Tetra Bio-Pharma (OTCQB:GRPOF) to supply dry medical cannabis under its ACMPR license and Tetra formulating and packaging under its CDSA dealer’s license in the maritime provinces and Quebec.
The commercial operations are likely to start in early summer 2017 with Tetra’s revenues commencing in 3Q17 and Aphria’s revenues commencing in 1Q18.
The distribution may expand into other provinces, subject of the success of the venture.
See important disclosures.
Now read: Aphria: A Well Oiled Machine »